Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of Erenumab and Oral Contraceptive
NCT02792517Phase 1Completed
- Sponsor
- Amgen
- Start
- Feb 2016
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of erenumab in migraine, sponsored by Amgen. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol, Area Under the Plasma Concentration Time Curve From Time 0 to 24 Hours Postdose (AUCtau) for Ethinyl Estradiol and 4 more. Started Feb 2016; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02792517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792517.